Everest Medicines Has Received Approval for the New Drug Application (NDA) for Nefecon® in Taiwan, Aimed at Treating Primary IGA Nephropathy in Adult Patients

Everest Medicines Has Received Approval for the New Drug Application (NDA) for Nefecon® in Taiwan, Aimed at Treating Primary IGA Nephropathy in Adult Patients

Everest Medicines has declared that the Taiwan Food and Drug Administration (TFDA) has accepted its New Drug Application (NDA) for Nefecon® for the treatment of primary immunoglobulin A nephropathy (IgAN) in adult patients. Nefecon® is the first treatment for IgAN approved in the U.S., European Union, and mainland China. The company expects approval in Taiwan in 2024.Rogers Yongqing Luo, CEO of Everest Medicines, expressed satisfaction with the expansion to Taiwan after recent NDA approvals in China and NDA acceptance in South Korea. The Asian population has a high prevalence of IgAN, posing a significant risk of progression to end-stage renal diseases.

Nefecon® received Accelerated Approval Designation (AAD) from the Taiwan FDA in Nov. 2022. The Phase 3 NefIgArd clinical trial demonstrated statistically significant and clinically meaningful benefits of Nefecon® over placebo in preserving kidney function for patients with IgAN.

The full two-year results of the NefIgArd trial, involving 364 patients, showed clinically meaningful preservation of kidney function in both Asian and White subgroups. Everest Medicines aims to offer Nefecon® to patients in various Asian territories in 2024, including Singapore, Hong Kong, Taiwan, and South Korea.

Nefecon® is a patented oral, delayed-release formulation of budesonide, a corticosteroid designed to target mucosal B-cells in the ileum where IgAN originates. Everest Medicines holds exclusive rights to develop and commercialize Nefecon® in Mainland China, Hong Kong, Macau, Taiwan, Singapore, and, as of March 2022, South Korea, through a licensing agreement with Calliditas Therapeutics AB.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!